The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: A comparison with desferrioxamine

European Journal of Pharmacology

Volumn 589, Issue 1-3, 2008, Pages 1-7

  Gharagozloo, Marjan ^a   Khoshdel, Zahra ^a   Amirghofran, Zahra ^a,b,c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Desferrioxamine; Flavonoid; Iron chelator; Jurkat cell line; Silybin; Silybum marianum

Indexed keywords

DEFEROXAMINE; IRON; REACTIVE OXYGEN METABOLITE; SILIBININ;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DRUG EFFECT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IRON CHELATION; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ANTIOXIDANTS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DEFEROXAMINE; DNA REPLICATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IRON; IRON CHELATING AGENTS; JURKAT CELLS; LEUKEMIA, T-CELL; SILYMARIN; TIME FACTORS;

EID: 47549095827     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.03.059     Document Type: Article

References (43)

1. Agarwal R., Agarwal C., Ichikawa H., Singh R.P., and Aggarwal B.B. Anticancer potential of silymarin: from bench to bedside. Anticancer Res. 26 (2006) 4457-4498
2. Alidoost F., Gharagozloo M., Bagherpour B., Jafarian A., Sajjadi S.E., and Hourfar H. Effects of silymarin on the proliferation and glutathione levels of peripheral blood mononuclear cells from beta-thalassemia major patients. Int. Immunopharmacol. 6 (2006) 1305-1310
3. Borsari M., Gabbi C., Ghelfi F., Grandi R., Saladini M., Severi S., and Borella F. Silybin, a new iron-chelating agent. J. Inorg. Biochem. 85 (2001) 123-129
4. Brodie C., Siriwardana G., Lucas J., Schleicher R., Terada N., Szepesi A., Gelfand E., and Seligman P. Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res. 53 (1993) 3968-3975
5. Bruggisser R., von Daeniken K., Jundt G., Schaffner W., and Tullberg-Reinert H. Interference of plant extracts, phytoestrogens and antioxidants with the MTT tetrazolium assay. Planta Med. 68 (2002) 445-448
6. Chaston T.B., Lovejoy D.B., Watts R.N., and Richardson D.R. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin. Cancer Res. 9 (2003) 402-414
7. Darnell G., and Richardson D.R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood 94 (1999) 781-792
8. Dayani P.N., Bishop M.C., Black K., and Zeltzer P.M. Desferoxamine (DFO)-mediated iron chelation: rationale for a novel approach to therapy for brain cancer. J. Neurooncol. 67 (2004) 367-377
9. Dietzmann J., Thiel U., Ansorge S., Neumann K.H., and Tager M. Thiol-inducing and immunoregulatory effects of flavonoids in peripheral blood mononuclear cells from patients with end-stage diabetic nephropathy. Free Radic. Biol. Med. 33 (2002) 1347-1354
10. El Hajji H., Nkhili E., Tomao V., and Dangles O. Interactions of quercetin with iron and copper ions: complexation and autoxidation. Free Radic. Res. 40 (2006) 303-320
11. Fernandez M.T., Mira M.L., Florencio M.H., and Jennings K.R. Iron and copper chelation by flavonoids: an electrospray mass spectrometry study. J. Inorg. Biochem. 92 (2002) 105-111
12. Gazak R., Walterova D., and Kren V. Silybin and silymarin-new and emerging applications in medicine. Curr. Med. Chem. 14 (2007) 315-338
13. Gharagozloo M., and Amirghofran Z. Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells. J. Cancer Res. Clin. Oncol. 133 (2007) 525-532
14. Hider R.C., Liu Z.D., and Khodr H.H. Metal chelation of polyphenols. Methods Enzymol. 335 (2001) 190-203
15. Hileti D., Panayiotidis P., and Hoffbrand A.V. Iron chelators induce apoptosis in proliferating cells. Br. J. Haematol. 89 (1995) 181-187
16. Huang X., Dai J., Fournier J., Ali A.M., Zhang Q., and Frenkel K. Ferrous ion autoxidation and its chelation in iron-loaded human liver HepG2 cells. Free Radic. Biol. Med. 32 (2002) 84-92
17. Lang I., Deak G., Nekam K., Muzes G., Gonzalez-Cabello R., Gergely P., and Feher J. Hepatoprotective and immunomodulatory effects of antioxidant therapy. Acta Med. Hung. 45 (1988) 287-295
18. Lang I., Nekam K., Deak G., Muzes G., Gonzales-Cabello R., Gergely P., Csomos G., and Feher J. Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers. Ital. J. Gastroenterol. 22 (1990) 283-287
19. Le N.T., and Richardson D.R. Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21 (CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation. Carcinogenesis 24 (2003) 1045-1058
20. Lederman H.M., Cohen A., Lee J.W., Freedman M.H., and Gelfand E.W. Desferrioxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 64 (1984) 748-753
21. Lucas J.J., Szepesi A., Domenico J., Takase K., Tordai A., Terada N., and Gelfand E.W. Effects of iron-depletion on cell cycle progression in normal human T lymphocytes: selective inhibition of the appearance of the cyclin A-associated component of the p33cdk2 kinase. Blood 86 (1995) 2268-2280
22. Lui Z.D., and Hider R.C. Design of iron chelators with therapeutic application. Coord. Chem. Rev. 232 (2002) 151-171
23. Mira L., Fernandez M.T., Santos M., Rocha R., Florencio M.H., and Jennings K.R. Interactions of flavonoids with iron and copper ions: a mechanism for their antioxidant activity. Free Radic. Res. 36 (2002) 1199-1208
24. Moridani M.Y., Pourahmad J., Bui H., Siraki A., and O'Brien P.J. Dietary flavonoid iron complexes as cytoprotective superoxide radical scavengers. Free Radic. Biol. Med. 34 (2003) 243-253
25. Nurtjahja-Tjendraputra E., Fu D., Phang J.M., and Richardson D.R. Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood 109 (2007) 4045-4054
26. Pan Y.J., Hopkins R.G., and Loo G. Increased GADD153 gene expression during iron chelation-induced apoptosis in Jurkat T-lymphocytes. Biochim. Biophys. Acta 1691 (2004) 41-50
27. Pietrangelo A., Borella F., Casalgrandi G., Montosi G., Ceccarelli D., Gallesi D., Giovannini F., Gasparetto A., and Masini A. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology 109 (1995) 1941-1949
28. Pradhan S.C., and Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J. Med. Res. 124 (2006) 491-504
29. Rahman I., Biswas S.K., and Kirkham P.A. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem. Pharmacol. 72 (2006) 1439-1452
30. Ramos S. Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. J. Nutr. 18 (2007) 427-442
31. Regis G., Bosticardo M., Conti L., De Angelis S., Boselli D., Tomaino B., Bernabei P., Giovarelli M., and Novelli F. Iron regulates T-lymphocyte sensitivity to the IFN-gamma/STAT1 signaling pathway in vitro and in vivo. Blood 105 (2005) 3214-3321
32. Renton F.J., and Jeitner T.M. Cell cycle-dependent inhibition of the proliferation of human neural tumor cell lines by iron chelators. Biochem. Pharmacol. 51 (1996) 1553-1561
33. Richardson D.R. Iron chelators as therapeutic agents for the treatment of cancer. Crit. Rev. Oncol. Hematol. 42 (2002) 267-281
34. Shatrov V.A., Boelaert J.R., Chouaib S., Droge W., and Lehmann V. Iron chelation decreases human immunodeficiency virus-1 Tat potentiated tumor necrosis factor-induced NF-kappa B activation in Jurkat cells. Eur. Cytokine Netw. 8 (1997) 37-43
35. Tam T.F., Leung-Toung R., Li W., Wang Y., Karimian K., and Spino M. Iron chelator research: past, present, and future. Curr. Med. Chem. 10 (2003) 983-995
36. Tenopoulou M., Doulias P.T., Barbouti A., Brunk U., and Galaris D. Role of compartmentalized redox-active iron in hydrogen peroxide-induced DNA damage and apoptosis. Biochem. J. 387 (2005) 703-710
37. Thomasset S.C., Berry D.P., Garcea G., Marczylo T., Steward W.P., and Gescher A.J. Dietary polyphenolic phytochemicals-promising cancer chemopreventive agents in humans? A review of their clinical properties. Int. J. Cancer 120 (2007) 451-458
38. Traore H.N., and Meyer D. Comparing qualitative and quantitative spectroscopic techniques for the detection of the effect of direct iron loading of mammalian cell cultures. Methods Cell Sci 23 (2001) 175-184
39. Valenzuela A., and Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol. Res. 27 (1994) 105-112
40. Voest E.E., Vreugdenhil G., and Marx J.J. Iron-chelating agents in non-iron overload conditions. Ann. Intern. Med. 120 (1994) 490-499
41. Wang S.T., Jin K.L., and Li T.H. The inhibitory effect of desferrioxamine on DNA synthesis in human lymphocytes. Chin. Med. J. 102 (1989) 902-905
42. Wilasrusmee C., Kittur S., Shah G., Siddiqui J., Bruch D., Wilasrusmee S., and Kittur D.S. Immunostimulatory effect of Silybum marianum (milk thistle) extract. Med. Sci. Monit. 8 (2002) BR439-BR443
43. Yu Y., Wong J., Lovejoy D.B., Kalinowski D.S., and Richardson D.R. Chelators at the cancer coalface: desferrioxamine to triapine and beyond. Clin. Cancer Res. 12 (2006) 6876-6883